Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Silverline Cu 380 Ag is a non-hormonal intrauterine device (IUD) developed by DKT WomanCare International in partnership with Pregna International for long-acting reversible contraception. The device features a flexible T-shaped frame with copper wire wound around the vertical stem, providing a total copper surface area of 380 mm². A distinguishing feature of the Silverline series is the inclusion of a silver core within the copper wire, which is designed to prevent fragmentation of the wire and maintain the structural integrity of the device over its effective lifespan. The primary mechanism of action involves the continuous release of copper ions into the uterine cavity, which are toxic to spermatozoa, thereby inhibiting sperm motility and viability and preventing fertilization. Additionally, the presence of the device induces a sterile inflammatory response in the endometrium that further interferes with sperm transport and potentially prevents implantation. It is approved for use and typically provides contraceptive protection for up to 5 years.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Silverline Cu 380 Ag.